Sermorelin vs Tirzepatide

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Sermorelin

Sermorelin is a synthetic analog of GHRH consisting of the first 29 amino acids of the natural hormone. It was previously FDA-approved for GH deficiency diagnosis and treatment in children.

Full details →

Tirzepatide

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.

Full details →

Side-by-Side Comparison

AspectSermorelinTirzepatide
MechanismBinds to GHRH receptors in the pituitary gland to stimulate natural GH production and release. Maintains the body's natural feedback mechanisms for GH regulation.Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, providing synergistic effects on insulin secretion, appetite suppression, and metabolic regulation. The dual mechanism may explain its enhanced efficacy.
Typical DosageTypical dosing: 200-500mcg administered once daily, usually before bed. Some protocols use twice daily dosing.Start at 2.5mg weekly, titrate every 4 weeks through 5mg, 7.5mg, 10mg, 12.5mg, to maximum 15mg weekly. Full titration takes approximately 20 weeks.
AdministrationSubcutaneous injection, preferably at bedtime to work with natural GH release patterns. Can be combined with GHRPs for synergistic effects.Subcutaneous injection once weekly. Rotate injection sites. Slower titration may help reduce GI side effects.
Side EffectsGenerally well-tolerated. May cause injection site reactions, headache, flushing, or dizziness. Less side effects than direct GH administration.Similar to semaglutide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite. Generally improve with continued use.
Best For

What They Have in Common

Both Sermorelin and Tirzepatide are commonly used for:

Key Differences

Ready to Learn More?